Hansoh Pharmaceutical Group

The phase‑III ARTEMIS‑011 study in China showed that Risvutatug Rezetecan (Ris‑Rez) statistically significantly improved progression‑free survival versus chemotherapy in relapsed osteosarcoma. Secondary endpoints, including overall survival, showed consistent benefits, and the safety profile was in line with previous findings with no new safety signals. Hansoh will use the data for a regulatory submission in China. » Mere på de.investing.com

The Phase-III ARTEMIS-008 study of risvutatug rezetecan conducted in China met its primary endpoint, showing a statistically significant improvement in overall survival versus standard therapy with topotecan. Key secondary endpoints, including progression-free survival, were also positive, and the safety profile was consistent with previous findings with no new signals. Hansoh Pharma will use the data for a regulatory submission in China; GSK holds exclusive rights outside mainland China, Hong Kong, Macau and Taiwan and is conducting a global Phase-III study with regulatory-relevant data expected next year. » Mere på de.investing.com

Hansoh Pharmaceutical's shares plunged 5.4% on Tuesday to HK$38.06, hitting the lowest level since Jan. 7. The move followed the announcement of a zero-coupon convertible bond of HK$4.68 billion maturing in 2033, convertible into 81.55 million new shares (about 1.33% of the enlarged share capital). The company said it will invest the proceeds in R&D for oncology, the central nervous system, and metabolic and autoimmune diseases, but the conversion feature sparked investor concerns about dilution. » Mere på de.investing.com